<DOC>
	<DOC>NCT02710448</DOC>
	<brief_summary>The study is to treat metformin dose-escalation diabetic subjects of all stages of renal failure (stages 1-5) and compare their rates of erythrocyte metformin (best reflections of a possible accumulation than those of plasma) to the therapeutic range. A number of 12 patients by stage is considered, 60 patients in total.</brief_summary>
	<brief_title>May Metformin be Used in Renal Failure?</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diabetic patients not treated with metformin, no treatment diabetic or have been treated but poorly balanced (HbA1c&gt; 7%) and an applicant building with metformin; at any stage renal stable (stages 15 according to the classification MDRD) Patients aged 18 to 80 years; Patients with an assessment of renal function dating back more than 3 months; Patients whose renal function is stable, on the criterion of the absence of fluctuation over 30% of renal function of creatinine clearance in the last three months, a reference to renal function at least 3 months from the balance sheet inclusion is necessary. Patient over 80 years Patients incapacitated adults (protected under guardianship) No previous reference creatinine; Fluctuation over 30% of renal function (creatinine clearance) in the three months; Reduction in BMI of more than 5% during the last 3 months; Severe hepatic impairment (Child stage&gt; A); No reference to liver stages 35 Patients to be an Xray with injection of contrast.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>